APA (7th ed.) Citation

Van den Bent, M. J., Tesileanu, C. M. S., Wick, W., Sanson, M., Brandes, A. A., Clement, P. M., . . . Baumert, B. (2021). Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): Second interim analysis of a randomised, open-label, phase 3 study. The lancet. Oncology, 22(6), . https://doi.org/10.1016/S1470-2045(21)00090-5

Chicago Style (17th ed.) Citation

Van den Bent, Martin J., et al. "Adjuvant and Concurrent Temozolomide for 1p/19q Non-co-deleted Anaplastic Glioma (CATNON; EORTC Study 26053-22054): Second Interim Analysis of a Randomised, Open-label, Phase 3 Study." The Lancet. Oncology 22, no. 6 (2021). https://doi.org/10.1016/S1470-2045(21)00090-5.

MLA (9th ed.) Citation

Van den Bent, Martin J., et al. "Adjuvant and Concurrent Temozolomide for 1p/19q Non-co-deleted Anaplastic Glioma (CATNON; EORTC Study 26053-22054): Second Interim Analysis of a Randomised, Open-label, Phase 3 Study." The Lancet. Oncology, vol. 22, no. 6, 2021, https://doi.org/10.1016/S1470-2045(21)00090-5.